Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 6
2006 9
2007 18
2008 24
2009 32
2010 53
2011 44
2012 42
2013 51
2014 33
2015 36
2016 26
2017 19
2018 20
2019 10
2020 15
2021 16
2022 13
2023 1
2024 4
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Cited In for PMID: 16043829

443 results

Results by year

Filters applied: . Clear all
Page 1
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA; TRIBUTE Investigator Group. Herbst RS, et al. J Clin Oncol. 2005 Sep 1;23(25):5892-9. doi: 10.1200/JCO.2005.02.840. Epub 2005 Jul 25. J Clin Oncol. 2005. PMID: 16043829 Clinical Trial.
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.
Brunet L, Alexandre D, Lee J, Blanquer-Rosselló MDM, Bracquemond D, Guernet A, Chhouri H, Goupil M, Kherrouche Z, Arabo A, Mancini M, Cartier D, Yao S, Godefroy D, Dehedin J, Li JR, Duparc C, Jamme P, Vinchent A, Bérard C, Tulasne D, Arena S, Bardelli A, Cheng C, Cho BC, Wurtz O, Coulouarn C, Maraver A, Aaronson SA, Cortot AB, Anouar Y, Grumolato L. Brunet L, et al. Nat Commun. 2025 Aug 22;16(1):7853. doi: 10.1038/s41467-025-61788-w. Nat Commun. 2025. PMID: 40846697 Free PMC article.
Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status.
Taniguchi Y, Tamiya A, Osuga M, Harada D, Isa SI, Nakamura K, Mizumori Y, Shinohara T, Yanai H, Nakatomi K, Oki M, Mori M, Kuwako T, Yamazaki K, Tamura A, Ando M, Koh Y. Taniguchi Y, et al. BMC Pulm Med. 2024 Aug 24;24(1):407. doi: 10.1186/s12890-024-03212-5. BMC Pulm Med. 2024. PMID: 39182046 Free PMC article.
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer.
Gijtenbeek RGP, van der Noort V, Aerts JGJV, Staal-van den Brekel JA, Smit EF, Krouwels FH, Wilschut FA, Hiltermann TJN, Timens W, Schuuring E, Janssen JDJ, Goosens M, van den Berg PM, de Langen AJ, Stigt JA, van den Borne BEEM, Groen HJM, van Geffen WH, van der Wekken AJ. Gijtenbeek RGP, et al. ERJ Open Res. 2022 Oct 17;8(4):00239-2022. doi: 10.1183/23120541.00239-2022. eCollection 2022 Oct. ERJ Open Res. 2022. PMID: 36267895 Free PMC article.
443 results